162 related articles for article (PubMed ID: 38570849)
1. Trends in antidiabetic drug use and expenditure in public hospitals in Northwest China, 2012-21: a case study of Gansu Province.
Cao W; Feng H; Yang Y; Wang L; Wang X; Ma Y; Zhao D; Hu X
BMC Health Serv Res; 2024 Apr; 24(1):415. PubMed ID: 38570849
[TBL] [Abstract][Full Text] [Related]
2. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
[TBL] [Abstract][Full Text] [Related]
3. Trends in antidiabetic drug utilization and expenditure in Denmark: A 22-year nationwide study.
Bang C; Mortensen MB; Lauridsen KG; Bruun JM
Diabetes Obes Metab; 2020 Feb; 22(2):167-172. PubMed ID: 31486269
[TBL] [Abstract][Full Text] [Related]
4. Long-term trend of antibiotic use at public health care institutions in northwest China, 2012-20 -- a case study of Gansu Province.
Cao W; Feng H; Ma Y; Zhao D; Hu X
BMC Public Health; 2023 Jan; 23(1):27. PubMed ID: 36604660
[TBL] [Abstract][Full Text] [Related]
5. Antidiabetic drug utilization in hungary.
Hankó B; Tukarcs E; Kumli P; Vincze Z
Pharm World Sci; 2005 Jun; 27(3):263-5. PubMed ID: 16096899
[TBL] [Abstract][Full Text] [Related]
6. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
Zhao B; Wu J
Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
[TBL] [Abstract][Full Text] [Related]
7. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals.
Meng Q; Cheng G; Silver L; Sun X; Rehnberg C; Tomson G
Health Policy Plan; 2005 May; 20(3):185-96. PubMed ID: 15840634
[TBL] [Abstract][Full Text] [Related]
8. Growth of diabetes drug expenditure decomposed-A nationwide analysis.
Soppi A; Heino P; Kurko T; Maljanen T; Saastamoinen L; Aaltonen K
Health Policy; 2018 Dec; 122(12):1326-1332. PubMed ID: 30297302
[TBL] [Abstract][Full Text] [Related]
9. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
[TBL] [Abstract][Full Text] [Related]
10. Antidiabetic medications use trends in an Andalusian region from 2001 to 2014.
López-Sepúlveda R; García Lirola MÁ; Espínola García E; Jurado Martínez JM; Martín Sances S; Anaya Ordóñez S; Cabeza Barrera J
Prim Care Diabetes; 2017 Jun; 11(3):254-264. PubMed ID: 28126469
[TBL] [Abstract][Full Text] [Related]
11. Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study.
Wang X; Huang H; Sun Y; Zhu Z; Jiang B; Yang L
BMJ Open; 2023 Jul; 13(7):e064199. PubMed ID: 37407064
[TBL] [Abstract][Full Text] [Related]
12. Access to and price trends of antidiabetic, antihypertensive, and antilipidemic drugs in outpatient settings of the Universal Coverage Scheme in Thailand.
Limwattananon C; Waleekhachonloet O
PLoS One; 2019; 14(2):e0211759. PubMed ID: 30785916
[TBL] [Abstract][Full Text] [Related]
13. The impact of National Centralised Drug Procurement policy on the use of policy-related original and generic drugs in China.
Yang Y; Hu R; Geng X; Mao L; Wen X; Wang Z; Hao S; Cui D; Mao Z
Int J Health Plann Manage; 2022 May; 37(3):1650-1662. PubMed ID: 35132676
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic Expenditure by Public Healthcare Institutions in Shandong Province in China, 2012-2016.
Yin J; Wu C; Wei X; Sun Q
Front Pharmacol; 2018; 9():1396. PubMed ID: 30559665
[No Abstract] [Full Text] [Related]
16. Impact of the zero-mark-up drug policy on drug-related expenditures and use in public hospitals, 2016-2018: an interrupted time series study in Shaanxi.
Yan K; Yang C; Zhang H; Ye D; Liu S; Chang J; Jiang M; Zhao M; Fang Y
BMJ Open; 2020 Nov; 10(11):e037034. PubMed ID: 33243788
[TBL] [Abstract][Full Text] [Related]
17. The vacated space of volume/price of the drugs centralized procurement with quantity in secondary and above public hospitals of China.
Wang J; Zhang S; Wang C; Li J; Wang R; Zhu L
BMC Health Serv Res; 2024 Jun; 24(1):771. PubMed ID: 38951849
[TBL] [Abstract][Full Text] [Related]
18. Improving the performance of social health insurance system through increasing outpatient expenditure reimbursement ratio: a quasi-experimental evaluation study from rural China.
Miao Y; Gu J; Zhang L; He R; Sandeep S; Wu J
Int J Equity Health; 2018 Jun; 17(1):89. PubMed ID: 29940956
[TBL] [Abstract][Full Text] [Related]
19. The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs.
Chen CL; Chen L; Yang WC
BMC Public Health; 2008 Apr; 8():118. PubMed ID: 18405385
[TBL] [Abstract][Full Text] [Related]
20. The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data.
Li BX; Wang YQ; Yi YY; Zhou N; Lv ZX; Ma R; Li X; Yuan N
BMC Public Health; 2024 May; 24(1):1309. PubMed ID: 38745323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
